> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Issues EIR for Aurobindo Pashamylaram Unit 4
- URL: https://www.fdaweb.com/fda-issues-eir-for-aurobindo-pashamylaram-unit-4/
- Published: 2020-02-19T12:00:00.000Z
- Updated: 2026-09-14T16:03:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146125

FDA has sent Aurobindo Pharma an Establishment Inspection Report (EIR) for Unit 4 of the company’s general injectable formulation manufacturing facility on Pashamylaram, Hyderabad, India. A [report](https://www.livemint.com/companies/news/aurobindo-pharma-gets-us-fda-inspection-report-for-pashamylaram-unit-11582090309891.html?ref=fdaweb.com) on the Indian Web site *Livemint* says the company did not disclose details of the EIR in its regulatory filing.

FDA inspected the facility 11/4-11/13/19 and issued an FDA-483 with 14 inspection observations, the report says. At the time, the company said it believes that none of the inspection observations were related to data integrity issues.